Shopping Cart
- Remove All
Your shopping cart is currently empty
DEG-35 is a CRBN-dependent bifunctional degrader targeting IKZF2 and CK1α, with DC50 values of 1.4 nM and 4.4 nM for CK1α and IKZF2, respectively. It activates the p53 apoptotic pathway and is applicable for research related to acute myeloid leukemia (AML).

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks |
| Description | DEG-35 is a CRBN-dependent bifunctional degrader targeting IKZF2 and CK1α, with DC50 values of 1.4 nM and 4.4 nM for CK1α and IKZF2, respectively. It activates the p53 apoptotic pathway and is applicable for research related to acute myeloid leukemia (AML). |
| In vitro | DEG-35 (10 and 100 nM) induces significant dose-dependent apoptosis and myeloid differentiation in MOLM-13 cells after 2 days. |
| In vivo | The half-life of DEG-35 (ip) in mouse plasma is 2.5 hours. In BL/6 mice transplanted with MLL-AF9 CrbnI391V cells, DEG-35 (ip, 50 mg/kg) slows the progression of leukemia without significant weight loss. |
| Molecular Weight | 443.45 |
| Formula | C25H21N3O5 |
| Cas No. | 2734910-37-1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.